SAN ANTONIO, Texas — Powerhouse Therapeutics Inc today announced that it will highlight new preclinical findings for its lead candidate, PH102, during the San Antonio Liver Cancer Symposium (SALCS), held October 11–12 at the Hilton Palacio del Rio.
PH102 is an autologous, “triple-threat” CAR T-cell therapy engineered to attack glypican-3-positive hepatocellular carcinoma through simultaneous tumor killing, immune activation, and micro-environment remodeling. Recent in vivo studies show deep, durable tumor regression without safety-limiting toxicity.
Chief Scientific Officer Gang Huang, PhD will deliver the oral presentation “CAR T-cell-based Triple-Hit Immunotherapy for Hepatocellular Carcinoma” on Friday, October 11, at 9:30 a.m. in the Liver Cancer Immunology session. Chief Executive Officer Vincent Pham will present a poster on PH102 during the symposium’s poster reception that afternoon at 3:45 p.m.
“Our data suggest PH102 can overcome key resistance pathways that limit current therapies,” said Dr. Huang. “We look forward to sharing these results with the liver cancer community.”
Mr. Pham added, “SALCS brings together leading clinicians, researchers, and industry partners. Presenting here underscores our commitment to rapid translation of PH102 into first-in-human trials.”
Hosted by the Mays Cancer Center at UT Health San Antonio, SALCS offers two days of plenary talks, panel discussions, and continuing-education programming designed to advance the prevention and treatment of liver cancers.
About Powerhouse therapeutics
Powerhouse Therapeutics Inc is a biotechnology company developing cell-based therapies that tackle treatment resistance in solid tumors and fibrotic diseases. Built on our proprietary Immune Triad Therapy with Armed CAR T-cell Supercharger (IT-ACTS) platform, we engineer multimodal living drugs that deliver targeted payloads, remodel the tumor microenvironment, and restore tissue homeostasis. Our lead candidate, PH102, is an autologous IT-ACTS therapy poised for clinical entry, with off-the-shelf and anti-fibrotic programs advancing in parallel. Founded by leading academic scientists, we combine academic rigor with translational speed to deliver paradigm-shifting therapies for all patients.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including those regarding our future results of operations and financial position, business strategy, product candidates, and planned clinical trials, are forward-looking statements. You can identify these statements by words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “potential,” “continue,” or similar expressions, as well as discussions of future events or trends.
Forward-looking statements are subject to many risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, delays or failures in product development, clinical-trial outcomes that differ from preclinical data, adverse decisions by regulatory authorities, challenges in manufacturing or supply chains, our ability to secure and protect intellectual-property rights, competition in the marketplace, changes in healthcare regulations, and our need for additional financing. More information about these and other risks is included in our filings with the U.S. Securities and Exchange Commission.
We caution readers not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Powerhouse Therapeutics Inc undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or circumstances, except as required by law.
